Investors are buzzing about Miromatrix Medical (USA Stocks: MIRO), a key player in the biotechnology industry, as insider confidence appears to be on the rise. The company's recent performance indicators are painting a promising picture. The Total Risk Alpha, a measure of the difference between a portfolio's expected return and the return it would have achieved without specific risks, stands at a robust
7.77. This suggests that the company is effectively managing its risk and generating higher returns than expected. Moreover, the company's Risk Adjusted Performance, which measures the risk of a portfolio compared to the risk of a benchmark, is at
0.0789, indicating that the company is outperforming its peers in the industry. The Jensen Alpha, a risk-adjusted measure of a portfolio's excess return, is at
4.53, further demonstrating the company's ability to generate superior returns. With these positive indicators, it's no wonder that insiders are showing increased confidence in Miromatrix Medical.
Important Points
We provide investment recommendations to supplement the latest
expert consensus on Miromatrix Medical. Our advanced recommendation engine utilizes a multidimensional algorithm to analyze the company's growth potential, taking into account all available technical and fundamental data at the time.
The successful prediction of Miromatrix Medical
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Miromatrix Medical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Miromatrix Medical based on Miromatrix Medical hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Miromatrix Medical's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Miromatrix Medical's related companies.
Use Technical Analysis to project Miromatrix expected Price
Miromatrix Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Miromatrix Medical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Miromatrix Medical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...A Deeper Perspective
Miromatrix Medical reported the previous year's revenue of 953.47
K. Net Loss for the year was (29.96
M) with loss before overhead, payroll, taxes, and interest of (466.93
K).
| 2020 | 2021 | 2022 | 2023 (projected) |
Revenues USD | 46.53 K | 33.07 K | 953.47 K | 1.03 M | Revenues | 46.53 K | 33.07 K | 953.47 K | 1.03 M |
Deferred Revenue Breakdown
Miromatrix Medical Deferred Revenue yearly trend continues to be very stable with very little volatility. Deferred Revenue is likely to drop to about 1.3
M. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. At this time, Miromatrix Medical's Deferred Revenue is very stable as compared to the past year.
| 2010 | 488,368 |
| 2021 | 980,101 |
| 2022 | 1.47 Million |
| 2023 | 1.34 Million |
"Never put all your eggs in one basket" is a proverb that resonates well with the current situation of Miromatrix Medical (USA Stocks: MIRO). Despite the company's current valuation standing at a robust
$73.6M, it's essential to note that the company's revenue is at a modest $953.47K, indicating a high price to sales ratio of 1,921X. This might suggest an overvaluation, but the high Z Score of 9.1 and low probability of bankruptcy at 26.78% point towards a healthy financial situation. Furthermore, the company's insider ownership stands at 23.53%, which may signal growing confidence within the company's management. However, with a downside deviation of 5.08 and a standard deviation of 27.22, the risk involved is substantial. Therefore, while there is potential upside, investors should consider the inherent risks and not put all their eggs in the Miromatrix basket.
Will price continue to roll up in December 2023?
Miromatrix Medical Inc. (MIRO) recently reported a Sortino ratio of 0.6, indicating a moderate risk-adjusted performance. Although this figure does not necessarily imply high profitability, it does suggest a degree of stability in the company's returns, taking into account downside risk. Consequently, it is reasonable to anticipate that MIRO's stock price may continue its upward trend in December 2023. However, investors should closely monitor the company's
financial health and market conditions, as these factors could significantly impact the stock's performance. Miromatrix Medical has exhibited above-average volatility over the chosen time period. Investors should independently evaluate Miromatrix Medical to ensure that their intended
market timing strategies align with their expectations about the company's volatility. Understanding different
market volatility trends can often assist investors in timing the market.
Proper use of volatility indicators allows traders to gauge Miromatrix Medical's stock risk against market volatility during both bullish and bearish trends. The increased level of volatility that accompanies bear markets can directly affect
Miromatrix Medical's stock price, adding stress for investors as they watch the value of their shares decline. This typically prompts investors to rebalance their portfolios by purchasing different stocks as prices drop. In light of the recent market data, the decision to exit Miromatrix Medical stock should be carefully considered. The company's Valuation Hype Value stands at
2.52, indicating a potentially overhyped valuation compared to its Real Value of
2.77. However, the Analyst Overall Consensus is a 'Strong Buy', with the Analyst Target Price Estimated Value set at 3. This suggests a possible upside price of 31.88, significantly higher than the possible downside price of 0.0334. Therefore, despite the current market valuation, the strong buy recommendation and potential for significant upside make it worth considering holding onto Miromatrix Medical stock for the time being. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Miromatrix Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
